SAN DIEGO, September 12, 2022 – Cellics Therapeutics, Inc., a biotechnology company pioneering Cellular Nanoparticle (CNP) platform technology for drug development and delivery, announced today that the company has appointed Paul Daruwala as the…
Cellics Therapeutics Receives First IND Allowance by FDA for its Innovative Cellular Nanoparticle (CNP) Technology
(San Diego) May 3 rd , 2022 – Cellics Therapeutics, Inc., a biotech startup company using the innovative Cellular Nanoparticle (CNP) Technology for the treatment and prevention of infectious and inflammatory diseases, announced today that…
Cellics Announces the Receipt of CARB-X Award of Up to US$15 Million
San Diego, CA (October 21st) – Cellics announced today that it has received a CARB-X Award of up to US$15 Million to develop a new treatment for sepsis caused by drug-resistant Gram-positive and Gram-negative bacteria….
Cellics Therapeutics Announces the Publication of Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity in Nano Letters
SAN DIEGO, (June 17, 2020, Globe Newswire) — Cellics Therapeutics, Inc. (Cellics) announced today that results of the study that evaluates the potential benefits of macrophage and pulmonary epithelial nanosponges in neutralizing SARS-CoV-2 infectivity have…